N-Palmitoyl-D-glucosamine
N-Palmitoyl-D-glucosamine is an orally active TLR4 antagonist. N-Palmitoyl-D-glucosamine stably binds MD-2 with, preventing LPS-induced NF-κB signaling, decreases pro-inflammatory cytokines (IL-1β, TNF-α, and IL-6), increases anti-inflammatory IL-10 and IL-1rα, and normalizes miR-20a-5p, miR-106a-5p, and miR-27a-3p levels. N-Palmitoyl-D-glucosamine decreases allodynia and prevents myelino-axonal degeneration of peripheral nerves. N-Palmitoyl-D-glucosamine can be used for the researches of keratitis and peripheral neuropathy.
For research use only. We do not sell to patients.
- CAS No.: 54627-18-8
- Formula: C22H43NO6
- Molecular Weight:417.58
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
|
IL-1β |
IL-6 |
IL-10 |
IL-1rα |
N-Palmitoyl-D-glucosamine stably binds MD-2 protein with a 1:3 stoichiometry, forming stable interactions with specific residues lining the protein's hydrophobic pocket[1].
N-Palmitoyl-D-glucosamine (10-20 µg/mL; 10 min pre-incubation, 5 h LPS stimulation) prevents LPS (HY-D1056)-induced NF-κB activation in NF-κB-transfected RAW264.7 cells[1].
N-Palmitoyl-D-glucosamine (10 µM) does not activate or inhibit human TRPA1 channels in stably transfected HEK293 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
N-Palmitoyl-D-glucosamine (20 mg/kg; i.p.; single dose 15 minutes before LPS) prevents LPS-induced thermal pain hypersensitivity in CD1 mice, as measured by tail-flick latency[1].
N-Palmitoyl-D-glucosamine (2.5-10 mg/kg; p.o.; single dose 30 minutes before formalin injection, then daily for 1 week) at 5 and 10 mg/kg reduces acute formalin-induced nociceptive behavior and persistent mechanical allodynia in CD1 mice, while a 2.5 mg/kg dose is ineffective[1].
N-Palmitoyl-D-glucosamine (20 mg/kg; p.o.; daily for 5 days before Oxaliplatin initiation, then daily for the duration of the protocol) prevents Oxaliplatin (HY-17371)-induced mechanical, cold allodynia and myelino-axonal degeneration of sciatic ner in CD1 mice with chemotherapy-induced peripheral neuropathy[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Keratitis CD1 (male, 25 g, LPS-induced keratitis)[1]
-
Dosage:5 mg/kg
-
Administration:p.o.; single dose 30 minutes before LPS injection; daily for 3 consecutive days starting 30 minutes after LPS injection
-
Result:Reduced LPS-induced keratitis clinical score.
Reduced LPS-induced ki67 levels and VEGF levels.
Normalized LPS-reduced miR-20a-5p and miR-106a-5p levels, reduced LPS-increased miR-27a-3p.
Lowered pro-inflammatory cytokines IL-1β, TNF-α, and IL-6, and increased anti-inflammatory IL-10 and IL-1rα.
-
Animal Model:Mechanical allodynia CD1 mice (male, 25 g, formalin-induced nociception and persistent mechanical allodynia)[1]
-
Dosage:2.5 mg/kg; 5 mg/kg; 10 mg/kg
-
Administration:p.o.; single dose 30 minutes before formalin injection, then daily for 1 week
-
Result:Reduced formalin-induced nocifensive behavior.
Increased mechanical withdrawal threshold.
Showed no significant effect on acute nocifensive behavior or persistent mechanical allodynia at 2.5 mg/kg.
Chemical Information
-
CAS No. 54627-18-8
-
Molecular Weight 417.58
-
Formula C22H43NO6
-
SMILES
OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)NC(CCCCCCCCCCCCCCC)=O
-
Structure Classification
-
Initial Source
Pseudomonas aeruginosa
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)